Analyses of apoptotic regulators CASP9 and DFFA at 1P36.2, reveal rare allele variants in human neuroblastoma tumours

F Abel¹, R-M Sjöberg¹, K Ejeskär¹, C Krona¹ and T Martinsson*¹

¹Department of Clinical Genetics, Gothenburg University, Sahlgrenska University Hospital/East, 85166 Gothenburg, Sweden

The genes encoding Caspase-9 and DFF45 have both recently been mapped to chromosome region 1p36.2, that is a region alleged to involve one or several tumour suppressor genes in neuroblastoma tumours. This study presents an update contig of the ‘Smallest Region of Overlap of deletions’ in Scandinavian neuroblastoma tumours and suggests that DFF45 is localized in the region. The genomic organization of the human DFF45 gene, deduced by in-silico comparisons of DNA sequences, is described for the first time in this paper. In the present study 44 primary tumours were screened for mutation by analysis of the genomic sequences of the genes. In two out of the 44 tumours this detected in the DFFA gene one rare allele variant that caused a non-polar to a polar amino acid exchange in a preserved hydrophobic patch of DFF45. One case was hemizygous due to deletion of the more common allele of this polymorphism. Out of 194 normal control alleles only one was found to carry this variant allele, so in respect of it, no healthy control individual out of 97 was homozygous. Moreover, our RT–PCR expression studies showed that DFF45 is preferably expressed in low-stage neuroblastoma tumours and to a lesser degree in high-stage neuroblastomas. We conclude that although coding mutations of Caspase-9 and DFF45 are infrequent in neuroblastoma tumours, our discovery of a rare allele in two neuroblastoma cases should be taken to warrant further studies of the role of DFF45 in neuroblastoma genetics.

British Journal of Cancer (2002) 86, 596–604. DOI: 10.1038/sj/bjc/6600111 www.bjcancer.com

Keywords: 1p-deletion; neuroblastoma; neuroectodermal; Apaf-3; DFF; ICAD

Neuroblastoma, a paediatric tumour originating in the neural crest cells, is a heterogeneous disease with tumour progression or spontaneous regression dependent on anatomic stage and age at diagnosis. Of a group of chromosomal aberrations proven to correlate with the prognosis of neuroblastoma, the most common are deletion in the short arm of 1p (1p36.2-3) and amplification of the proto-oncogene MYCN on 2p24.1 (reviewed in Brodeur, 1999). More recently, gain of parts of the long arm of chromosome 17 (17q gain) has also been shown to have prognostic value (Abel et al, 1999; Bown et al, 1999).

Apoptosis or programmed cell death (PCD) is responsible for the maintenance of homeostasis in tissues as well as in embryonic development. Called caspsases, the key apoptotic effectors comprise a family of cysteine proteases that requires cleavage after a specific internal Asp residue for activation (Li et al, 1997; Srinivasula et al, 1998). Caspase-9, a 45-kDa protein (also called ‘Apoptotic protease activating factor-3’, Apaf-3, ICE-LAP-6, Mch6), has been shown to be a critical and futhest upstream member of the mitochondrial-mediated apoptotic protease cascade (Li et al, 1997; Kuida et al, 1998; Srinivasula et al, 1998). Activated by Apaf-1-mediated oligomerization, Procaspase-9 in turn activates by proteolytic cleavage downstream caspasases such as caspase-3, -6 and -7 (Li et al, 1997; Srinivasula et al, 1998). Caspase-3 in turn cleaves a selected group of substrates that cause the morphological and biochemical changes that characterize apoptotic cell death. One of the caspase-3 downstream substrate proteins is DFF (DNA Fragmentation Factor; Liu et al, 1997; Enari et al, 1998; Halenbeck et al, 1998); it is a heterodimeric protein composed of one 40- and one 45-kDa subunit (Liu et al, 1997). DFF40 (synonymous names CPAN ‘Caspase-Activated Nuclease’/CAD ‘Caspase-Activated Dnase’) is a DNase that triggers both DNA fragmentation and chromatin condensation (Liu et al, 1997). DFFB could not be shown to be imprinted or to contain any somatic mutations in tumour samples. Gene-targeting studies of CASP9 have shown that it is important during brain development. A majority of CASP9 knockout mice has been shown to die perinatally with a markedly enlarged and malformed cerebrum caused by reduced apoptosis (Hakem et al, 1998; Kuida et al, 1998). No DFF45/ICAD-deficient mouse has shown any developmental...
abnormality, but some cell types have shown reduced DNA fragmentation and DNA condensation and are partially resistant to undergo apoptosis (Zhang et al., 1998, 1999).

Both the CASP9 (OMIM number 602234) and the DFFA (OMIM number 601882) genes have recently been localized to 1p36.2 (Leek et al., 1997; Hadano et al., 1999), a region commonly deleted in neuroblastoma tumours. DFFA is in fact localized in the 1p-deleted SRO (smallest region of overlap) at 1p36.2-3 defined by our group, and according to Ohira et al. (2000) within a homozgyously deleted region in a neuroblastoma cell line. CASP9 is localized at 1p36.21, approximately 4 Mb proximal to our SRO-region, but still in the region commonly deleted by neuroblastoma tumours. In the present study, the purpose of the present study was to investigate whether mutated CASP9 or DFFA could be causative in the development of neuroblastoma tumours in childhood.

MATERIALS AND METHODS

Patients and controls
DNA was extracted from frozen (−70°C) tumour samples obtained from 44 Scandinavian patients with neuroblastoma of all different stages (Table 1). Three were stage 1, three were stage 2A, one was stage 2B, 13 were stage 3, two were stage 4S, 17 were stage 4, and five were of unknown stages. Clinical data were derived from Martinsson et al. (1995) and from unpublished data. The neuroblastomas were staged according to the International Neuroblastoma Staging System criteria (INSS; Brodeur et al., 1993). DNA was also extracted from EDTA-blood obtained from 97 normal control individuals from western Sweden. If a DNA variation was found in a patient, in general, 47 normal controls were screened in order to determine the normal allele frequency of this variant (i.e. 94 alleles). If the polymorphism could not be found in this set of 47, another set of 50 normal controls were screened (i.e. in total 194 alleles).

Mapping and BAC (bacterial artificial chromosome)-contig construction
CASP9 and DFFA were mapped by running an alignment search (BLAT-search) of each of the complete coding sequences (NM_001229 and NM_001229) on ‘Golden path’ at UCSC (http://genome.ucsc.edu; Figure 1A). BACs were found by screening a BAC-library (Research Genetics, Huntsville, AL, USA). Some of the 16 BACs in the present study are from earlier published results (Ejeskar et al., 2001); while some are new (Figure 1B). BAC-ends were sequenced using Big Dye Terminator chemistry (Applied Biosystems, Foster City, CA, USA) and the universal T7- and SP6-primers. The BAC-contig was constructed by running alignment searches of seven markers (D1S508, GATA4H04, D1S214, GGTATGC03, D1S160, D1S503 and D1S244) and all available BAC-end sequences on ‘Golden path’ at UCSC. The markers and BACs were then aligned to UCSC-clones (Figure 1B). Marker D1S244 and the DFFA (exons 1 and 5) and the CORT genes, were fine-mapped by PCR-assay (data not shown) against four BACs (318-F24, 513-I12, 347-P23 and 387-I22; Figure 1C). All PCR’s were run with positive and negative controls, and against two different colonies from the same BAC.

PCR-amplification
Primer sequences for CASP9 and DFFA were selected by means of the DNASTAR primer select software (LASERGENE, Madison, WI, USA; data available on request). Primers for CASP9 were constructed from the nine published exon sequences (Figure 2A) and the mRNA sequence (GenBank accession numbers: AB019197 (exon 1); AB019198 (exon 2); AB019199 (exon 3); AB019200 (exon 4); AB019201 (exon 5); AB019202 (exon 6); AB019203 (exon 7); AB019204 (exon 8); AB019205 (exon 9); NM_001229 (mRNA)). The promoter region of the CASP9 gene could not be investigated, because the CASP9 upstream sequence was not available. Primers for DFFA exons and promoter were constructed from the sequence of an unfinished chromosome 1 clone (GenBank accession number: AL354956) and from the mRNA sequence (GeneBank accession number: NM_004401). Forward (F) and reverse (R) primers were synthesized using an ABI Applied Biosysyem 392 DNA/RNA Synthesizer (Applied Biosystems) or ordered from Life Technologies (www.invitrogen.com; Life Technologies, Inc. Gaitherburg, MD, USA). Amplifications were performed according to standard procedures at our laboratory (for details see Abel et al., 1999) with 30 cycles of 30–45 s at 95°C, 30–45 s at 52–64°C (dependent on which exon) and 60 s at 72°C.

DNA-sequencing
Sequencing was performed with an ABI PRISM 377 DNA Sequencer (Applied Biosystems). The sequencing reactions were made with ABI PRISM Big Dye Terminator Cycle Sequencing Ready Reaction Kit (Applied Biosystems). The PCR-products were purified with QIAquick Spin PCR purification kit (Qiagen, Hilden, Germany) or the Multiscreen PCR; 96 well purification system (Millipore Corporation, Bedford, MA, USA), and the concentrations of the PCR-products were estimated by comparison to a 100 bp-mass ladder on a 2% agarose gel. The sequence reaction products were precipitated and diluted according to standard procedures at our laboratory (for details see Abel et al., 1999). The samples were denatured for 3 min at 95°C on a thermo block, and loaded on a 7% acryl amide gel.

In-silico cloning of DFFA
The genomic structure of the DFFA gene was determined by in-si-co cloning. A BLAT-search of the DFFA complete coding sequence (GenBank accession number: NM_004401) was performed against ‘unfinished hts’. One of the three hits was the unfinished chromosome 1 clone with GenBank accession number: AL354956, which was used to determine the DFFA genomic structure (Figure 3A and Table 2). To find a likely promoter region of DFFA we used NNPP – Eukaryotic promoter prediction by neural network available at BCM Search Launcher (URL: http://searchlauncher bcm.tmc.edu/seq-search/gene-search.html); the TSSG, and the TSSW-human PolII recognition programs at the same URL were used to predict the most likely Polymerase II binding site.

Expression analysis
cDNA was extracted and synthesized according to RNasy (Qiagen) and Superscript II (Promega, Madison, WI, USA) protocols. The cDNA quality was tested by PCR with GADP-primers: sense, 5′-GGGAGGGCCAAAAGGGTCATCCTC-3′, and antisense, 5′-GAGGCGGCCATCCACAGTCTTCT-3′ with 30 standard cycles of amplification (30–45 s at 95°C, 30–45 s at 60°C and 60 s at 72°C). This primer pair spans two introns (intron no. 5 and 6), and generates a cDNA band at 235 bp and a genomic band at 520 bp. cDNAs showing positive PCR-results for the genomic band (520 bp) were not included in this study.

The expression of CASP9, its alternatively spliced variant CASPS9, and the total expression of DFFA were tested by RT–PCR. The long (encoding DFF45) and the short alternatively spliced forms (encoding DFF35) of DFFA were not distinguished.
(primers are available on request). Amplifications were carried out in 50 μl and performed for 30–35 standard cycles of amplification (30–45 s at 95°C, 30–45 s at 50°C and 60 s at 72°C). The results were analyzed by running 10 μl PCR product on an ethidium bromide stained 2% agarose gel (Figure 4). All expression results were checked three times.

RESULTS

Mapping and construction of BAC-contig

According to BLAT-searches in UCSC (http://genome.ucsc.edu), CASP9 is localized to 1p36.21 and DFFA is localized to 1p36.22 very near marker D1S244 (Figure 1A). Based on the order of the seven markers according to UCSC (D1S508, GATA4H04, D1S214, GGAT3G04, D1S160, D1S503 and D1S244), the SRO of deletions

Table 1 Summary of clinical parameters and experimental data from patients with neuroblastoma

| Clinical parameters | NB stage | 1p-del | MYCN | 1q gain |
|---------------------|----------|--------|-------|---------|
| 156                 | 1        | —      | —     | —       |
| 161                 | 1        | —      | —     | —       |
| 181                 | 1        | —      | —     | +       |
| 133                 | 2A       | —      | nd    | —       |
| 177                 | 2A       | —      | nd    | —       |
| St 156              | 1        | —      | —     | —       |
| St 127              | 2B       | —      | —     | —       |
| St 128              | 3        | nd     | —     | —       |
| St 135              | 3        | nd     | —     | +       |
| St 136              | 3        | nd     | —     | +       |
| St 157              | 3        | —      | —     | —       |
| St 187              | 3        | —      | —     | +       |
| St 99               | 3        | +      | —     | +       |
| St 100              | 3        | —      | —     | +       |
| St 124              | 3        | +      | —     | +       |
| St 131              | 3        | +      | —     | +       |
| St 149              | 3        | +      | —     | —       |
| St 158              | 3        | —      | —     | +       |
| St 164              | 3        | —      | —     | +       |
| St 208              | 3        | +      | —     | +       |
| St 125              | 4S       | nd     | —     | —       |
| St 162              | 4S       | —      | —     | —       |
| St 41               | 4        | —      | —     | —       |
| St 55               | 4        | +      | —     | —       |
| St 95               | 4        | +      | —     | +       |
| St 106              | 4        | +      | —     | +       |
| St 112              | 4        | —      | —     | —       |
| St 114              | 4        | —      | —     | (+)     |
| St 123              | 4        | nd     | —     | —       |
| St 155              | 4        | +      | —     | +       |
| St 184              | 4        | +      | —     | +       |
| St 189              | 4        | +      | —     | +       |
| St 102              | 4        | +      | —     | +       |
| St 119              | 4        | +      | —     | —       |
| St 129              | 4        | +      | —     | (+)     |
| St 153              | 4        | +      | —     | —       |
| St 172              | 4        | (+)/−  | —     | —       |
| St 190              | 4        | +/−    | —     | —       |
| St 116              | 4        | +      | —     | —       |
| St 142              | 4        | +      | —     | +       |
| St 108              | 4        | +      | —     | +       |
| St 174              | 4        | +      | —     | —       |
| St 196              | 4        | +      | —     | —       |

Column 1: Sample name; column 2: NB stage; column 3: 1p-deletion; column 4: MYCN-amplification; column 5: 17q gain; column 6: unknown stage; column 7: +, MYCN-amplification; column 8: −, no MYCN-amplification; column 9: (±), uncertain results (according to Abel et al., 1999).

Table 2 Sequences at the DFFA splice junctions

| Exon | Position | Length | Splice acceptor sequence | Splice donor sequence |
|------|----------|--------|--------------------------|-----------------------|
| 1    | 5'-UTR   | 192    | ATGGAGGTGACCGGGGACGC      | GTTGGCTCGGGACCCCGGCC  |
| 2    | 5'-UTR   | 162    | ATGGGCATACAACAATTCAG     | GTAAAGAACCCTAGCCATGT |
| 3    | 5'-UTR   | 143    | TATCAGAGGAGGACCTCCAG     | GTAAAGCCTCCTCCACAACC |
| 4    | 5'-UTR   | 190    | CCTCTTGTCAAAGCAGGAAG     | GTAGGACTCTCTGCAGGCAG |
| 5a   | 5'-UTR   | 152    | TATCTAGTCAGGATTTGGAG     | GTGGGCGGAAACCAGGGTCA |
| 5b   | 5'-UTR   | ?      | TATCTAGTCAGGATTTGGAG     | GTGGGCGGAAACCAGGGTCACTGA |
| 5a   | 3'-UTR   | 794    | TATCTAGTCAGGATTTGGAG     | GTGGGCGGAAACCAGGGTCA |

Column 1: DFFA exons; column 2: Position; column 3: Length; column 4: Splice acceptor sequence; column 5: Splice donor sequence; column 6: 5'-UTR; column 7: 3'-UTR.
that our group had previously defined (D1S508, D1S244, Ejeskar et al., 2001) is now localized proximal to marker D1S214 and distal to marker D1S244 (Figure 1B). Fifteen of the 16 BACs included in this study reside in this region. According to distances in the UCSC brow-
Addition, two of the 47 normal controls were heterozygous for this polymorphism in their corresponding constitutional DNA. In 2B). The three patients detected to be heterozygous also displayed threonine to isoleucine (ACC

\(?\) and as homozygous (T/T) in one patient (case 136, Figure 2). The 305C

\(?\) polymorphism in exon 2 caused substitution of codon 102 from a amino acid residue substitutions (305C

\(?\) T and 662A

\(?\) G) and the third was a silent mutation (408T

\(?\) >C). The 305C

\(?\) >T polymorphism in exon 2 caused substitution of codon 102 from a threonine to isoleucine (ACC

\(?\) →ATC) and we detected it as heterozygous (C/T) in three neuroblastoma patients (cases 156, St100 and St172) and as homozygous (T/T) in one patient (case 136, Figure 2B). The three patients detected to be heterozygous also displayed this polymorphism in their corresponding constitutional DNA. In addition, two of the 47 normal controls were heterozygous for this polymorphism (Table 3). The 662A

\(?\) >G polymorphism in CASP9 exon 5 caused a substitution of codon 221 from a glutamine to arginine (CAG

\(?\) →CGG); we found it to occur frequently. All 44 tumours showed linkage disequilibrium for polymorphisms IVS1-36G

\(?\) >A, 408T

\(?\) >C and 662A

\(?\) >G. The two strict haplotypes seen were (1) A-C-G and (2) G-T-A. Of the 44 tumours, 12 were homozygous for haplotype 1; 14, of which three were informative hemizygous, were homozygous for haplotype 2; and 18 were heterozygous. Of the 48 normal controls 13 were homozygous for haplotype 1; 12 were homozygous for haplotype 2; and 23 were heterozygous (Table 3).

CASP9 studies - expression analysis

CASP9 was expressed in all neuroblastoma stages (Figure 4). A slightly weaker expression could be seen in high-stage tumours (stage 3 and 4). CASP9 was strongly expressed in the ganglioneuroma, both tumours of stage 1, and both stage 4S tumours. Four out of five stage 3 tumours showed CASP9 expression. Ten out of 14 stage 4 tumours showed CASP9 expression; four of them (case 126, 106, St129, and St130B) showed a strong expression, while the other three were very weak. The expression of the alternatively spliced form, CASP9S, in general showed the same expression pattern as CASP9 (data not shown).

DFFA studies - genomic structure of DFFA

The genomic structure of the DFFA gene was determined by in-silico cloning from an unfinished chromosome 1 clone.
(GenBank accession number: AL354956; Table 2). DFFA is organized as 6 exons (five smaller and one large) over a genomic stretch of approximately 11 kb (Figure 3A). The length of intron no. 1 could not be determined due to a gap of unknown size in the clone. No splicing of intron 5 generates the alternatively spliced form, encoding DFF35. The mRNA generated by this isoform contains normal exons 1 to 4, and a 24 bp-

extended exon 5 (exon 5b, Table 2). Two different promoter sites were predicted for the forward strand of the DFFA promoter sequence (NNPP – Eucaryotic promoter prediction by neural network; LMNL): the first between –249 to –198 from the DFFA transcription start point, and the second between –21 to +29 from the DFFA transcription start point. Use of the TSSG and TSSW-human PolII recognition programs did not

Figure 3  Schematic representation of the DFFA gene. (A) Exon-intron organization of the gene corresponding to approximately 11 kb. Exons are numbered from 1 – 6 in the 5’-3’ direction. Light shaded boxes represent the coding regions of each exon. Dark shaded boxes represent the 5’- and 3’-untranslated flanking regions (UTR’s). The 5’ UTR is 56 bp and the most 3’ UTR is 581 bp long. The 3’ UTR of the alternatively spliced fragment after exon 5 is of unknown size. The start and stop codons are indicated by arrows. The black bars represent the eight amplified fragments (promoter-region, exon 1, 2, 3, 4, 5, 6; 1 and 6: 2). The dotted line represents the normal splicing of DFFA, encoding DFF45. The 206T>C polymorphism detected in DFFA exon 2. Upper panel: Amplified tumour-DNA from case 184, hemizygous -/C. Middle panel: Amplified constitutional DNA from case 184 (extracted from blood), heterozygous T/C. Lower panel: Amplified constitutional DNA from control Q170 (from blood), homozygous T/T. (B) Rare polymorphism detected in DFFA. The 206T>C polymorphism located in DFFA exon 2. Case St 108; cDNA tumour T/C. (C) Amplified tumour-cDNA from case St 108, heterozygous T/C. (D) The amino acid sequence of DFF45 (GenBank accession number: NP_004392). The upper sequence represents the DFF45 (331 aa) amino acid sequence, and the lower sequence represents the DFF35 (268 aa) amino acid sequence. The arrows denote the aspartic acid (D) residue after which the caspase-3 cleavage occurs (Liu et al., 1997; Sakahira et al., 1998). Letters coloured red (residues 12 – 100) represent the conserved N-terminal domain; CIDE (Cell-death Inducing DFF45-like Effector; Zhou et al., 2001). The bold and circled residue indicates the polymorphic site where the amino acid substitution takes place. Isoleucine (I) is exchanged for threonine (T), caused by the 206T>C base pair substitution.

Figure 4  RT – PCR expression analysis of CASP9 and DFFA from all stages of neuroblastoma. GN, ganglioneuroma; 1, 2B, 3, and 4, stages of neuroblastoma; +, positive control. Upper panel: Tumour extracted cDNA amplified by RT – PCR with CASP9-primers. Middle panel: Tumour extracted cDNA amplified by RT – PCR with DFFA-primers. Lower panel: GAPDH control cDNA amplified by RT – PCR with GAPDH primers (see text). From left to right: GN, case St 151; stage 1, 118, 161; stage 4S, 125, 162; stage 3, 157, 187, St 124, St 131, St 149; stage 4, 32, 114, 126, 168, 169, 111, St 153, 95, 106, 155, 174, St 102, St 129, St 130; positive control, St 64.
Table 3  Allele frequencies detected in CASP9 and DFFA

| Gene | Exon | Detected polymorphism | Allele frequency | Effect |
|------|------|-----------------------|------------------|--------|
|      |      |                       | Patients         | Normals|         |
| CASP9 | 1    | none                  | 42/88            | 49/94 | non-coding |
|       | 2    | IVS1-36G>A            | 5/88             | 2/96  | Thr->Ile |
|       |      | 305C>T                | 42/88            | 49/94 | silent   |
|       | 3    | none                  | 42/88            | 49/94 | silent   |
|       | 5    | 662A>G                | 42/88            | 49/94 | Gln->Arg |
|       | 6    | none                  |                  |       |          |
|       | 7    | none                  |                  |       |          |
|       | 8    | none                  |                  |       |          |
|       | 9    | none                  |                  |       |          |
| DFFA  | Prom | none                  |                  |       | non-coding |
|       | 1    | IVS0-466T>C           | 8/88             | 8/94  |          |
|       | 2    | IVS2+40A>G            | 43/88            | 106/194 | non-coding |
|       | 3    | none                  | 3/88             | 1/194 | Ile->Thr |
|       | 4    | none                  |                  |       |          |
|       | 5    | none                  |                  |       |          |
|       | 6    | none                  |                  |       |          |

Rare allele variants are shown in bold.

predict any polymerase II binding sites in the DFFA promoter sequence.

DFFA studies – detection and analysis of polymorphisms

In DFFA, three different polymorphisms were detected by sequence analysis: one in the promoter region (IVS0-466T>C; GenBank accession number: NM 004401). One out of 44 tumours was homozygous (C/C) for the rare variant of this polymorphism, and six out of 44 were heterozygous (T/C). Eight out of 47 normal controls were heterozygous (T/C) for this polymorphism, and none of the samples analyzed were detected in approximately the same frequency in patients and normal controls, and none of the samples analyzed diverged from this pattern. Using RT–PCR, we found that caspase-9 and caspase-9S exhibited the same expression pattern, but that the expression in high stage tumours was slightly lower for both isoforms (Figure 4).

DISCUSSION

The heterozygous 1p-deleted SRO in neuroblastoma had already been defined both by our group (Martinsson et al, 1995; Ejeskar et al, 2001) and by others (Takeda et al, 1994; Caron et al, 1995; White et al, 1995; Hogarty et al, 2000). In the present study, we discuss an update contig of our SRO region that based on alignment searches using 'Golden path' at UCSC (http://genome.ucsc.edu; Figure 1B). The 500 kb homozgyously deleted region on 1p36.2 in a neuroblastoma cell line (Ohira et al, 2000) partially overlaps our SRO (Figure 1B,C). A number of suggested but also rejected candidate tumour suppressor genes have been investigated (Maris et al, 1997; Martinsson et al, 1997; Grenet et al, 1998; Ejeskar et al, 1999, 2000). We have previously analyzed in detail one of the genes believed to reside in our SRO-region, and in the region defined by Ohira et al (2000), i.e. CORT (Ejeskar et al, 2000) without finding evidence of any role in neuroblastoma tumorigenesis (Figure 1C). In the present study we have examined two other genes in neuroblastoma primary tumours, CASP9 and DFFA. Caspase-9 has been shown to be a key effector of the apoptotic pathway in the nervous system (Hakem et al, 1998; Kuida et al, 1998) and DFF45 (encoded by DFFA) an important regulatory subunit of the DNA fragmentation factor involved in apoptosis. Both genes (CASP9 and DFFA) have been localized to 1p36.2 (Leek et al, 1997; Hadano et al, 1999; Figure 1A).

Like CORT, DFFA is believed to be localized both to our SRO-region (D1S214-D1S244) and the region defined by Ohira et al, 2000; Ejeskar et al, 2001; Figure 1C,D. However, since DFFA maps very close to marker D1S244, it was uncertain whether the gene is localized distal or proximal to this marker. PCR-assay against BACs mapped to the region of UCSC suggests that it is distal and therefore resides in our SRO-region (Figure 1C). This suggestion would accord with the proposed gene order in this region as suggested by both UCSC (http://genome.ucsc.edu) and Ohira et al (2000) (Figure 1D).

For four neuroblastoma primary tumours were analyzed by sequence analysis for mutations in the coding region of the CASP9 and DFFA genes, and in the promoter region of DFFA. In CASP9, we found two polymorphisms causing amino acid substitutions (305C>T and 662A>G). The first was rare and caused a polar (threonine) to a non-polar (isoleucine) substitution, with only three out of 44 heterozygous and one out of 44 homozygous (T/T; see Figure 2A). The three heterozygous individuals also showed this polymorphism in their constitutional normal DNA. In the homozygous patient (case 136), the constitutional normal DNA was not available and CASP9-LOH could not be determined. This case 136 could therefore be hemizygous (-T) for this polymorphism. We found that the 305C>T polymorphism had the same frequency (4%) in normal controls, but only in the heterozygous form.

There are several conserved regulatory motifs in caspase-9 (Figure 2C). Its large subunit contains the conserved active siteArg Cys. The catalytic Cys residue is conserved between human caspase-9 and CED-3 ('C. elegans' homologue) homologous domains in the presence of cytochrome c and dATP; they have been shown to contain a caspase recruitment domain (CARD) motif that contains several conserved hydrophobic residues (Hofmann et al, 1997; Zhou et al, 1999). Moreover, caspase-9 is negatively regulated by phosphorylation of the Ser-196 residue at the consensus motif 'RRRES' (Cardone et al, 1998; Figure 2C). No polymorphism found in this study could be shown to reside in any of these regulatory sites, but polymorphisms IVS-36G/A, 408T/C and 662A/G, clearly exhibited two different strict haplotypes; both were detected in approximately the same frequency in patients and normal controls, and none of the samples analyzed diverged from this pattern. Using RT–PCR, we found that caspase-9 and caspase-9S exhibited the same expression pattern, but that the expression in high stage tumours was slightly lower for both isoforms (Figure 4).
In the present study we describe the genomic organization of the DFFA gene. The gene is organized as six exons (Table 2 and Figure 3A), which is the same as that of the murine ICAD gene (Kawahara et al., 1999). Other similarities are the alternatively spliced isoforms encoding murine ICAD-S or human DFF35, which are both generated by no splicing of intron 5. In DFFA we found one polymorphism in the promoter-region in five of 44 patients (IVS0-466T>C). One stage 3 neuroblastoma tumour (St158) was homozygous for the rare allele (C); eight of 47 normal controls (T/C). This polymorphism is located only nine bases downstream of a predicted TFIIID-binding site (-TATATTTTTA-; as suggested by TESS-search for transcription factor binding sites).

In exon 2 of DFFA, two of 44 patients displayed one rare polymorphism in the coding region (206 T>C) that caused an amino acid substitution of codon 69 from a non-polar to a polar amino acid (Isoleucine to Threonine; Figure 3D). Case 184 was hemizygous -/-C (Table 1 and Figure 3B), due to deletion, and case St108 was heterozygous (T/C). The constitutional DNA of both these two patients was heterozygous (T/C) for this polymorphism in. Only one of 97 normal controls (1%) showed this polymorphism in the heterozygous form, compared to two out of 44 of the neuroblastoma patients (4%; Table 3). Strikingly, the normal allele (T) was deleted in case 184 while only the rare C allele was retained in the tumour. However, RT–PCR based sequence analysis of the cDNA from case St108 revealed that both alleles (T and C) were expressed in this tumour (Figure 3C). DFF45 is a protein that comprises 331 amino acids (Figure 3D). In the short isoform, DFF35, the first 261 amino acids are identical. Both DFF45 and DFF35 carry two caspase-3-recognition sites (amino-acid positions 117 and 224; Sakahira et al., 1998; Gu et al., 1999). As only the full-length DFF45 functions as a chaperone for DFF40 (Sakahira et al., 2000), amino acids 261 to 331 seem relevant to this function (Gu et al., 1999). Zhou et al. (2001) have recently reported that the N-terminal domain (NTD) of DFF45 (residues 12–100) is homologous to the NTD of DFF40. Moreover, the NTD of DFF45 is alone unstructured in solution, and its folding is induced upon binding to DFF40 NTD. Therefore, deletion of NTD from either DFF40 or DFF45 results in the production of an inactive nuclease. Interestingly, the preserved convex hydrophobic patch of DFF40 forms van der Waal contact with the preserved concave hydrophobic patch of DFF45, through interaction between Ala-86/Tyr-75, Val-21/Val-70, and Phe-19/Ile-69 from DFF40 and DFF45, respectively (Zhou et al., 2001). The 206 T>C mutation/polymorphism variant causing a substitution of Ile-69, found in this study, could therefore disturb the hydrophobic contact between the NTD’s. If it does, no active nucleases would be produced during apoptosis in the homozygous mutant/poly-morphic cells. In the present study, we also investigated the expression of DFFA in neuroblastoma tumours (Figure 4). We selected primers of which both the normal and the alternatively spliced variant were amplified by the same PCR reaction. We detected expression of DFFA in tumours of all different stages, but found a noteworthy difference between that in low-stage and high-stage tumours. It was not or very poorly expressed in stages 3 and 4, which accords with an earlier study (Ohiira et al., 2000).

We would conclude by suggesting that caspase-9, and, in particular, DFF45 are good candidates for the supposed tumour suppressor on 1p36.2-3. Firstly, the biology of these genes that are key players of the apoptotic signalling system renders them attractive as neuroblastoma candidate genes. Secondly, they both map to the consensus region deleted in all neuroblastoma cases with 1p deletion while DFFA also maps within the 500 kb region of homozygous loss in a neuroblastoma cell line characterized by Ohiira et al. (2000). Thirdly, we detected in two neuroblastoma cases an interesting variant polymorphism in DFFA that in one case retained as the sole allele in a tumour where the common allele had been lost by deletion. This allele variant was present only in one normal allele out of the 194 that we tested. Fourthly, low-stage tumours expressed the two genes much more distinctly than did the high-stage tumours. This was especially pronounced for DFFA: its expression in high-stage tumours was very low or absent. We would therefore suggest that, at present, neither gene be ruled out as a candidate for a neuroblastoma tumour suppressor gene. We hope that this conclusion will prompt others to study these genes, in particular DFFA, in their neuroblastoma tumour material.

ACKNOWLEDGEMENTS

We wish gratefully to acknowledge the financial support of the Swedish Cancer Society, the Children’s Cancer Foundation, the King Gustav V Jubilee Clinic Cancer Research Foundation, and the Assar Gabrielsson Foundation.

REFERENCES

Abel F, Ejeskar K, Kogner P, Martinsson T (1999) Gain of chromosome arm 17q is associated with unfavourable prognosis in neuroblastoma, but does not involve mutations in the somatostatin receptor 2 (SSTR2) gene at 17q24. Br J Cancer 81: 1402–1409
Bown N, Cotterill S, Lastowska M, O’Neill S, Pearson AD, Plantaz D, Meddeb S (1998) The human caspase-9 gene: isolation and characterization of the genomic DNA. Hum Mol Genet 7: 1253–1262
Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, Frisch S, Reed JC (1998) Regulation of cell death protease caspase-9 by phosphorylation (see comments). Science 282: 1318–1321
Caron H, Peter M, van Sluis P, Speleman F, de Kraker J, Laureys G, Michin J, Brugieres L, Voute PA (1993) Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment (see comments). J Clin Oncol 11: 1466–1477
Cordon-Cardo C, Baylin SB, Bigner DD (1998) The molecular basis of hereditary neurofibromatosis. Nat Genet 20: 253–258
Ejeskar K, Abel F, Sjöberg R, Backstrom J, Kogner P, Martinsson T (2000) Fine mapping of the human preprocortistatin gene (CORT) to neuroblastoma consensus deletion region 1p36.3–p36.2, but absence of mutations in primary tumours. Cytogenet Cell Genet 89: 62–66
Ejeskar K, Sjöberg R, Abel F, Kogner P, Ambros P, Martinsson T (2001) Fine mapping of a tumour suppressor candidate gene region in 1p36.3-2.3, commonly deleted in neuroblastomas and germ cell tumours. Med Pediatr Oncol 36: 61–66
Ejeskar K, Sjöberg RM, Kogner P, Martinsson T (1999) Variable expression and absence of mutations in p73 in primary neuroblastoma tumours argues against a role in neuroblastoma development. Int J Mol Med 3: 585–589
Enari M, Sakahira H, Yokoyama H, Okawa K, Iwamatsu A, Nagata S (1998) A caspase-activated DNase that degrades DNA during apoptosis, an inhibitor ICAD (see comments) (published erratum appears in Nature 1998 May 28;393(6683):396). Nature 391: 43–50
Grenet J, Valentine V, Kitson J, Li H, Farrow SN, Kiddy VL (1998) Duplication of the DR3 gene on human chromosome 1p36 and its deletion in human neuroblastoma. Genomics 49: 385–393
Gu J, Dong RP, Zhang C, McLaughlin DF, Wu MX, Schlossman SF (1999) Functional interaction of DFF35 and DFF45 with caspase-activated DNA fragmentation nuclease DFF40. J Biol Chem 274: 20759–20762

Ejeskar K, Abel F, Sjöberg R, Backström J, Kogner P, Martinsson T (1999) Gain of chromosome arm 17q is associated with unfavourable prognosis in neuroblastoma, but does not involve mutations in the somatostatin receptor 2 (SSTR2) gene at 17q24. Br J Cancer 81: 1402–1409
Bown N, Cotterill S, Lastowska M, O’Neill S, Pearson AD, Plantaz D, Meddeb S (1998) The human caspase-9 gene: isolation and characterization of the genomic DNA. Hum Mol Genet 7: 1253–1262
Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, Frisch S, Reed JC (1998) Regulation of cell death protease caspase-9 by phosphorylation (see comments). Science 282: 1318–1321
Caron H, Peter M, van Sluis P, Speleman F, de Kraker J, Laureys G, Michin J, Brugieres L, Voute PA, Westerveld A, Slater R, Delattre O, Versteeg R (1998) Variable expression and absence of mutations in p73 in primary neuroblastoma tumours argues against a role in neuroblastoma development. Int J Mol Med 3: 585–589
Enari M, Sakahira H, Yokoyama H, Okawa K, Iwamatsu A, Nagata S (1998) A caspase-activated DNase that degrades DNA during apoptosis, an inhibitor ICAD (see comments) (published erratum appears in Nature 1998 May 28;393(6683):396). Nature 391: 43–50
Grenet J, Valentine V, Kitson J, Li H, Farrow SN, Kiddy VL (1998)Duplication of the DR3 gene on human chromosome 1p36 and its deletion in human neuroblastoma. Genomics 49: 385–393
Gu J, Dong RP, Zhang C, McLaughlin DF, Wu MX, Schlossman SF (1999)Functional interaction of DFF35 and DFF45 with caspase-activated DNA fragmentation nuclease DFF40. J Biol Chem 274: 20759–20762
Hanedan S, Nasir J, Nikolch K, Rasper DM, Vaillancourt JP, Sherer SW, Beatty BG, Ikeda JE, Nicholson DW, Hayden MR (1999) Genomic organization of the human caspase-9 gene on Chromosome 1p36.1-36.3. Mamm Genome 10: 757–760
Hakem R, Hakem A, Duncan GS, Henderson JT, Woo M, Soengas MS, Elia A, de la Pompa JL, Kagi D, Khoo W, Potter J, Yoshida R, Kaufman SA, Lowe SW, Penninger JM, Mak TW (1998) Differential requirement for caspase 9 in apoptotic pathways in vivo. Cell 94: 339–352
Halenbeck R, MacDonald H, Roulston A, Chen TT, Conroy L, Williams LT (1998) CPAN, a human nuclelease regulated by the caspase-sensitive inhibitor DFF45. Curr Biol 8: 537–540
Hofmann K, Bucher P, Tschopp J (1997) The CARD domain: a new apoptotic signalling motif. Trends Biochem Sci 22: 155–158
Hogarty MD, Liu X, Guo C, Thompson PM, Weiss MJ, White PS, Sulman EP, Brodeur GM, Maris JM (2000) Identification of a 1-megabase consensus region of deletion at 1p36.3 in primary neuroblastomas. Med Pediatr Oncol 35: 512–515
Ikeda H, Hirafo J, Akami M, Matsuyama S, Suzuki N, Takahashi A, Kuroiwa M (1995) Bcl-2 oncprotein expression and apoptosis in neuroblastoma. J Pediatr Surg 30: 805–808
Ikeda H, Nakamura Y, Hiwasa T, Sakiyama S, Kuida K, Su MS, Nakagawara A (1997) Interleukin-1 beta converting enzyme (ICE) is preferentially expressed in neuroblastomas with favourable prognosis. Eur J Cancer 33: 2081–2083
Judson H, van Roy N, Strain L, Vandsemoppe J, Van Gele M, Speleman F, Leek JP, Carr IM, Bell SM, Markham AF, Lench NJ (1997) Assignment of the human caspase-9 gene on Chromosome 1p36.1-36.3. Genomics 10: 757–760
Kuida K, Hayday TF, Kuan CY, Gu Y, Taya C, Karasuyama H, Su MS, Rakic P (1996) Reduced apoptosis and cytochrome c-mediated caspase activation in mice lacking caspase 9. Cell 94: 325–337
Leek JP, Carr IM, Bell SM, Markham AF, Lench NJ (1997) Assignment of the DNA fragmentation factor gene (DFFA) to human chromosome bands 1p36.3–gtp36.2 by in situ hybridization. Cyto.genet Cell Genet 79: 212–213
Li P, Nijhawan D, Buddhirdo J, Srinivasula SM, Ahmad M, Alnemri ES, Wang X (1997) Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 91: 479–489
Liu X, Li P, Widad P, Zou H, Luo X, Garrard WT, Wang X (1998) The 40-kDa subunit of DNA fragmentation factor induces DNA fragmentation and chromatin condensation during apoptosis. Proc Natl Acad Sci USA 95: 8461–8466
Liu X, Zou H, Slaughter C, Wang X (1997) DFF, a heterodimeric protein that functions downstream of caspase-3 to trigger DNA fragmentation during apoptosis. Cell 89: 175–184
Maris JM, Jensen J, Sulman EP, Beltinger CP, Allen C, Biegel JA, Brodeur GM, White PS (1997) Human Kruppel-related 3 (HKR3): a candidate for the 1p36 neuroblastoma tumour suppressor gene? Eur J Cancer 33: 1991–1996
Martinsson T, Sjoberg RM, Hallstensson K, Nordling M, Hedborg F, Kogner P (1997) Delimitation of a critical tumour suppressor region at distal 1p in neuroblastoma tumours. Eur J Cancer 33: 1997–2001
Martinsson T, Sjoberg RM, Hedborg F, Kogner P (1995) Deletion of chromosome 1p loci and microsatellite instability in neuroblastomas analyzed with short-tandem repeat polymorphisms. Cancer Res 55: 5681–5686
Meija MC, Navarro S, Pellini A, Castel V, Llombart-Bosch A (1998) Study of bcl-2 protein expression and the apoptosis phenomenon in neuroblastoma. Anticancer Res 18: 801–806
Ohira M, Kageyama H, Mihara M, Furuta S, Machida T, Shishikura T, Takayasu H, Islam A, Nakamura Y, Takahashi M, Tomitsui N, Sakiyama S, Kaneko Y, Toyoada A, Hattori M, Sakaki Y, Ohki M, Horii A, Sueda E, Inazawa J, Seki N, Kuma H, Nozawa I, Nakagawara A (2000) Identification and characterization of a 500-kb homozgyously deleted region at 1p36.2-p36.3 in a neuroblastoma cell line (in process citation). Oncogene 19: 4302–4307
Sakaihira H, Enari M, Nagata S (1998) Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis (see comments). Nature 391: 96–99
Sakaihira H, Iwamatsu A, Nagata S (2000) Specific chaperone-like activity of inhibitor of caspase-activated DNase for caspase-activated. DNAse N J Biol Chem 275: 8091–8096
Srinivasula SM, Ahmad M, Fernandes-Alnemri T, Alnemri ES (1998) Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization. Mol Cell 1: 949–957
Srinivasula SM, Fernandes-Alnemri T, Zangrilli J, Robertson N, Armstrong RC, Wang L, Trapani JA, Tomasselli KJ, Litwack G, Alnemri ES (1996) The Ced-3-interleukin ibeta converting enzyme-like homolog Mch6 and the lamin-cleaving enzyme Mch2alpha are substrates for the apoptotic mediator CPP32. J Biol Chem 271: 27099–27106
Takeda O, Homma C, Maseki N, Sakurai M, Kanda N, Schwab M, Nakamura Y, Kaneko Y (1994) There may be two tumor suppressor genes on chromosome arm 1p closely associated with biologically distinct subtypes of neuroblastoma. Genes Chromosomes Cancer 10: 30–39
Teitz T, Wei T, Valentine MB, Vanin EF, Greener J, Valentine VA, Behm FG, Look AT, Lahti JM, Kidd VI (2000) Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN (see comments). Nat Med 6: 529–533
White PS, Maris JM, Beltinger C, Sulman E, Marshall HN, Fujimori M, Kaufman BA, Biegel JA, Allen C, Hiiardi C, Valentine MB, Look AT, Enomoto H, Sakiyama S, Brodeur GM (1995) A region of consistent deletion in neuroblastoma maps within human chromosome 1p36.2-36.3. Proc Natl Acad Sci USA 92: 5520–5524
Zhang J, Liu X, Scherer DC, van Kuer L, Wang X, Xu M (1998) Resistance to DNA fragmentation and chromatin condensation in mice lacking the DNA fragmentation factor 45. Proc Natl Acad Sci USA 95: 12480–12485
Zhang J, Wang X, Bove KE, Xu M (1999) DNA fragmentation factor 45-deficient cells are more resistant to apoptosis and exhibit different dying morphology than wild-type control cells. J Biol Chem 274: 37450–37454
Zhou P, Lugovskoy AA, McCarty JS, Li P, Wagner G (2001) Solution structure of DNA fragmentation factor 45. Proc Natl Acad Sci USA 98: 6051–6055
Zhou P, Chou J, Olea RS, Yuan J, Wagner G (1999) Solution structure of Apaf-1 CARD and its interaction with caspase-9 CARD: a structural basis for specific adaptor/caspase interaction. Proc Natl Acad Sci USA 96: 11265–11270

Analyses of CASP9 and DFFA in human neuroblastoma
F Abel et al